Orano med
Pre-clinicalOrano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb)
Founded
2018
Employees
201-500
Focus
Small Molecules
About
Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb)
Funding History
1Total raised: $15M
Series A$15MUndisclosedMar 15, 2021
Company Info
TypePrivate
Founded2018
Employees201-500
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile